A Phase 2, Double Blind, Placebo Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome
Latest Information Update: 05 Nov 2021
At a glance
- Drugs RSLV 132 (Primary)
- Indications Sjogren's syndrome
- Focus Pharmacodynamics; Pharmacogenomic; Proof of concept
- Sponsors Resolve Therapeutics
- 02 Dec 2020 According to a Resolve Therapeutics media release, results were published in leading rheumatology journal, Arthritis and Rheumatology .
- 02 Dec 2020 Results published in Resolve Therapeutics Media Release.
- 15 Aug 2020 Results published in the Arthritis and Rheumatology